Pierre Fabre Taps XtalPi’s AI and Robotics for Drug Discovery
AI-generated summary Laboratoires Pierre Fabre and XtalPi announced an agreement on November 9, 2026, to discover novel small-molecule clinical candidates using artificial intelligence and robotics. XtalPi will provide artificial intelligence capabilities and a robotics platform for de novo design, while Laboratoires Pierre Fabre will select and advance compounds in oncology, dermatology, and rare diseases.